Skip to main content

Beta Cell Generation by Stem Cell-Derived Implants in Diabetes

Objective

Despite improved treatment, diabetes remains a chronic disease with major health risks and heavy burden on patients and society. Serious forms are caused by depletion in pancreatic beta cells and associated loss in insulin’s homeostatic control throughout life. Their cure requires restoration of a metabolically adequate beta cell mass. Implants of beta cell grafts prepared from human pancreases have shown proof-of-principle but also the need for developing a large-scale source for therapeutic cells. Our objective is to generate a functional beta cell mass by stem cell-derived implants in diabetes patients. A combined preclinical and clinical project will search recipient and implant conditions for formation and maturation of beta cells in subcutaneous implants of device-encapsulated pancreatic endodermal cells that are derived from human embryonic stem cells (hu-ES) and manufactured for clinical studies. We collected preclinical evidence for the therapeutic potential of this implant from comparison with clinically used human beta cell grafts. State-of-the art methods and markers have been developed to investigate the biology of implants and to monitor host immune and innate reactivity. This approach helps understand the basis for metabolic outcome and identify targets for improvement. Pilot studies examine the influence of the (auto)immune status of the patients. Data will determine transition to clinical efficacy studies, or indicate the need for further laboratory development. Implants in preclinical models will guide modifications in clinical protocols, and explore the biologic properties of grafts derived from human induced pluripotent stem cell (iPSc) as can also be prepared from diabetes patients. Our consortium joins innovating cells, methods, markers and minds in a unique combination of expert clinical, academic and industry activities that need each other to make progress in an ambitious program.

Field of science

  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /medical and health sciences/clinical medicine/endocrinology/diabetes
  • /medical and health sciences/medical biotechnology/medical bioproducts/implants

Call for proposal

H2020-PHC-2015-single-stage_RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

VRIJE UNIVERSITEIT BRUSSEL
Address
Pleinlaan 2
1050 Brussel
Belgium
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 3 100 000

Participants (6)

VIACYTE, INC CORPORATION
United States
EU contribution
€ 600 000
Address
General Atomics Court 3550
92121 San Diego Ca
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
OSPEDALE SAN RAFFAELE SRL
Italy
EU contribution
€ 1 200 000
Address
Via Olgettina 60
20132 Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 600 000
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
SOCIETE DES PRODUITS NESTLE SA
Switzerland
EU contribution
€ 0
Address
Avenue Nestle 55
1800 Vevey
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE
France
EU contribution
€ 100 000
Address
Boulevard De L'hopital 47
75013 Paris
Activity type
Research Organisations
CENTER FOR BETA CELL THERAPY IN DIABETES
Belgium
EU contribution
€ 600 000
Address
Laarbeeklaan 103
1090 Brussel
Activity type
Other